How PP211 Works
Crosses the Blood-Brain Barrier
Targets Tumor Cell Energy
Selectively Kills Tumor Cells
Works Independently of Glucose
PP211 Key Features
Once-Daily Oral
BBB Penetration Confirmed
Broad Oncology Potential
Low Toxicity Profile
Competitive Landscape — How PP211 Compares
Crosses the Blood-Brain Barrier
PP211: Confirmed ✓ | Temozolomide: Partial | Radiation Therapy: N/A | Novocure Optune: N/AIf customers can’t find it, it doesn’t exist. Clearly list and describe the services you offer. Also, be sure to showcase a premium service.
Low Systemic Toxicity
PP211: Yes ✓ | Temozolomide: No | Radiation Therapy: No | Novocure Optune: YesHaving a big sale, on-site celebrity, or other event? Be sure to announce it so everybody knows and gets excited about it.
No Hair / Weight Loss Expected
PP211: Yes ✓ | Temozolomide: No | Radiation Therapy: No | Novocure Optune: YesAre your customers raving about you on social media? Share their great stories to help turn potential customers into loyal ones.
Oral / Home Administration
PP211: Yes ✓ | Temozolomide: Yes | Radiation Therapy: No | Novocure Optune: NoRunning a holiday sale or weekly special? Definitely promote it here to get customers excited about getting a sweet deal.
Works in Treatment-Resistant Tumors
PP211: Yes ✓ | Temozolomide: No | Radiation Therapy: Limited | Novocure Optune: LimitedHave you opened a new location, redesigned your shop, or added a new product or service? Don't keep it to yourself, let folks know.
Intellectual Property & Validation
Patent: 1 — BPA Scaffold Compounds
Covers fenofibrate-derived metabolic anti-cancer compounds that inhibit mitochondrial respiration.
Patent: 2 — Benzo-Thiazole Scaffold (PP211)
PP211 is the lead compound — uniquely kills tumor cells without engaging glycolysis, providing treatment advantage across varying tumor microenvironments.
Exclusive License: LSU Health Sciences Center
WayPath holds exclusive, perpetual commercialization rights from LSU Health Sciences Center, New Orleans, for all covered compounds.
NIH STTR Grant Awarded — Competitive Federal Grant
NIH STTR Phase I grant awarded Q4 2022, validating scientific merit of PP211. Phase II application submitted Novermber 2025.